AMGN - Amgen Inc. Последние новости | Finranks

07.08.2026

Amgen: The Market Is Underestimating Its Next Growth Phase

The market has finally noticed Amgen's R&D achievements and progress in commercializing its key blockbusters in the treatment of cardiovascular diseases and IMIDs. So, sales of Tezspire, used to treat asthma and CRSwNP, rose 42.1% year-over-year to $486 million in the second quarter. On the other hand, Repatha, a PCSK9 inhibitor, generated $953 million in revenue for Amgen, up 8.8% quarter-on-quarter.

07.08.2026

Chubb, Toast And A Health Care Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Malcolm Ethridge, managing partner at Capital Area Planning Group, recommended Chubb Limited (NYSE:CB) as his final trade.

05.08.2026

Amgen: First $10 Billion Quarter, More Growth Ahead

Amgen Inc. delivered a strong Q2 results, beating revenue and EPS estimates, and raised full-year guidance by $1 billion and $0.50, respectively. Despite $7 billion in LOE headwinds, Amgen's commercial portfolio—driven by Repatha, Uplizna, Evenity, Tezspire, and Imdelltra—continues to outperform expectations. Key pipeline catalysts, including MariTide and olpasiran phase 3 readouts, are expected in 2027–2028, with near-term pipeline news flow remaining light.

05.08.2026

Amgen gains after strong quarterly results and continued product momentum

Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per share of $6.29 for the quarter, ahead of analyst estimates of roughly $5.60 to $5.62.

05.08.2026

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

05.08.2026

AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline

Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.

05.08.2026

Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
AMGN	Truist	Hold	$340 >> $362	August 5th 2026
AMGN	Oppenheimer	Outperform	$400 >> $450	August 5th 2026
AMGN	Morgan Stanley	Equal Weight	$333 >> $351	August 5th 2026
AMGN	RBC Capital Mkts	Outperform	$370 >> $400	August 5th 2026
AMGN	Robert W. Baird	Underperform	$215 >> $230	August 5th 2026
AMGN	BofA Securities	Underperform	$312 >> $317	August 5th 2026
AMGN	Canaccord Genuity	Hold	$366 >> $384	August 5th 2026
AMGN	Wells Fargo	Equal Weight	$390 >> $400	August 5th 2026

Пресс-релизы

05.08.2026

AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health Information

THOUSAND OAKS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Amgen data breach.

Amgen Inc. (AMGN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Amgen Inc. (AMGN)

Amgen: The Market Is Underestimating Its Next Growth Phase

Chubb, Toast And A Health Care Stock On CNBC's ‘Final Trades'

Amgen: First $10 Billion Quarter, More Growth Ahead

Amgen gains after strong quarterly results and continued product momentum

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline

Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health Information

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Search stocks

Amgen Inc. (AMGN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Amgen Inc. (AMGN)

Amgen: The Market Is Underestimating Its Next Growth Phase

Chubb, Toast And A Health Care Stock On CNBC's ‘Final Trades'

Amgen: First $10 Billion Quarter, More Growth Ahead

Amgen gains after strong quarterly results and continued product momentum

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline

Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health Information

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS